Association between augmented levels of the gut pro-hormone Proneurotensin and subclinical vascular damage.
Cardiovascular disease
Carotid intima-media thickness
Neurotensin
Proneurotensin
Pulse pressure
Subclinical vascular damage
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 07 2024
02 07 2024
Historique:
received:
15
02
2024
accepted:
26
06
2024
medline:
3
7
2024
pubmed:
3
7
2024
entrez:
2
7
2024
Statut:
epublish
Résumé
Elevated levels of the gut pro-hormone Proneurotensin (proNT) have been found to predict development of cardiovascular disease. However, it is still unknown whether higher proNT levels are associated with subclinical vascular damage. Herein, we investigated the relationship between higher proNT concentrations and augmented pulse pressure (PP) and carotid intima-media thickness (cIMT), indicators of increased arterial stiffness and subclinical atherosclerosis, respectively. Clinical characteristics, PP and cIMT were evaluated in 154 non-diabetic individuals stratified into tertiles according to fasting serum proNT concentrations. We found that, subjects with higher proNT levels exhibited a worse lipid profile and insulin sensitivity, increased C-reactive protein levels, along with higher values of PP and cIMT as compared to the lowest proNT tertile. Prevalence of elevated PP (≥ 60 mmHg) and subclinical carotid atherosclerosis (IMT > 0.9 mm) was increased in the highest tertile of proNT. In a logistic regression analysis adjusted for several confounders, subjects with higher proNT levels displayed a fivefold raised risk of having elevated PP values (OR 5.36; 95%CI 1.04-27.28; P = 0.05) and early carotid atherosclerosis (OR 4.81; 95%CI 1.39-16.57; P = 0.01) as compared to the lowest proNT tertile. In conclusion, higher circulating levels of proNT are a biomarker of subclinical vascular damage independent of other atherosclerotic risk factors.
Identifiants
pubmed: 38956152
doi: 10.1038/s41598-024-65992-4
pii: 10.1038/s41598-024-65992-4
doi:
Substances chimiques
proneurotensin
0
Protein Precursors
0
Neurotensin
39379-15-2
C-Reactive Protein
9007-41-4
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
15086Informations de copyright
© 2024. The Author(s).
Références
Roth, G. A. et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: Update from the GBD 2019 study. J. Am. Coll. Cardiol. 76(25), 2982–3021 (2020).
pubmed: 33309175
pmcid: 7755038
doi: 10.1016/j.jacc.2020.11.010
Vaduganathan, M., Mensah, G. A., Turco, J. V., Fuster, V. & Roth, G. A. The global burden of cardiovascular diseases and risk: A compass for future health. J. Am. Coll. Cardiol. 80(25), 23612371 (2022).
doi: 10.1016/j.jacc.2022.11.005
Powell-Wiley, T. M. et al. Obesity and cardiovascular disease: A scientific statement from the American Heart Association. Circulation 143(21), e984–e1010 (2021).
pubmed: 33882682
pmcid: 8493650
doi: 10.1161/CIR.0000000000000973
Volpe, M. & Gallo, G. Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC). Front. Cardiovasc. Med. 10, 1136340 (2023).
pubmed: 36993998
pmcid: 10040794
doi: 10.3389/fcvm.2023.1136340
Lopez-Jimenez, F. et al. Obesity and cardiovascular disease: Mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation. Eur. J. Prev. Cardiol. 29(17), 2218–2237 (2022).
pubmed: 36007112
doi: 10.1093/eurjpc/zwac187
Polak, J. M. et al. Specific localisation of neurotensin to the N cell in human intestine by radioimmunoassay and immunocytochemistry. Nature 270(5633), 183–184 (1977).
pubmed: 337160
doi: 10.1038/270183a0
Kalafatakis, K. & Triantafyllou, K. Contribution of neurotensin in the immune and neuroendocrine modulation of normal and abnormal enteric function. Regul. Pept. 170, 7–17 (2011).
pubmed: 21549161
doi: 10.1016/j.regpep.2011.04.005
Barchetta, I., Baroni, M. G., Melander, O. & Cavallo, M. G. New insights in the control of fat homeostasis: The role of neurotensin. Int. J. Mol. Sci. 23(4), 2209 (2022).
pubmed: 35216326
pmcid: 8876516
doi: 10.3390/ijms23042209
Li, J. et al. An obligatory role for neurotensin in high-fat-diet-induced obesity. Nature 533, 411–415 (2016).
pubmed: 27193687
pmcid: 5484414
doi: 10.1038/nature17662
Mazella, J., Béraud-Dufour, S., Devader, C., Massa, F. & Coppola, T. Neurotensin and its receptors in the control of glucose homeostasis. Front. Endocrinol. 3, 143 (2012).
doi: 10.3389/fendo.2012.00143
Rabinowich, L. et al. Sortilin deficiency improves the metabolic phenotype and reduces hepatic steatosis of mice subjected to diet-induced obesity. J. Hepatol. 62(1), 175–181 (2015).
pubmed: 25173968
doi: 10.1016/j.jhep.2014.08.030
Chen, C., Li, J., Matye, D. J., Wang, Y. & Li, T. Hepatocyte sortilin 1 knockout and treatment with a sortilin 1 inhibitor reduced plasma cholesterol in Western diet-fed mice. J. Lipid Res. 60(3), 539–549 (2019).
pubmed: 30670473
pmcid: 6399493
doi: 10.1194/jlr.M089789
Barchetta, I. et al. Neurotensin is a lipid-induced gastrointestinal peptide associated with visceral adipose tissue inflammation in obesity. Nutrients 10(4), 256 (2018).
doi: 10.3390/nu10040526
Koon, H. W. et al. Neurotensin induces IL-6 secretion in mouse preadipocytes and adipose tissues during 2,4,6,-trinitrobenzensulphonic acid-induced colitis. Proc. Natl. Acad. Sci. U S A 106, 8766–8771 (2009).
pubmed: 19443690
pmcid: 2688970
doi: 10.1073/pnas.0903499106
Castagliuolo, I. et al. Neurotensin is a proinflammatory neuropeptide in colonic inflammation. J. Clin. Invest. 103, 843–849 (1999).
pubmed: 10079105
pmcid: 408137
doi: 10.1172/JCI4217
Zhao, D. et al. Signal transduction pathways mediating neurotensin- stimulated interleukin-8 expression in human colonocytes. J. Biol. Chem. 276, 44464–44471 (2001).
pubmed: 11574537
doi: 10.1074/jbc.M104942200
Osadchii, O. E. Emerging role of neurotensin in regulation of the cardiovascular system. Eur. J. Pharmacol. 762, 184192 (2015).
doi: 10.1016/j.ejphar.2015.05.025
Osadchii, O., Norton, G., Deftereos, D., Badenhorst, D. & Woodiwiss, A. Impact and mechanisms of action of neurotensin on cardiac contractility in the rat left ventricle. Eur. J. Pharmacol. 520, 108117 (2005).
doi: 10.1016/j.ejphar.2005.07.014
Osadchii, O. E., Kanorskii, S. G., Pokrovskii, V. M., Kurzanov, A. N. & Skibitskii, V. V. Effects of regulatory peptides on electrophysiological properties of the human heart. Hum. Physiol. 27, 601605 (2001).
doi: 10.1023/A:1011972629867
Kérouac, R., Rioux, F. & St-Pierre, S. Mechanism of neurotensin-induced pressor effect and tachycardia in guinea pigs. Life Sci. 28, 24772487 (1981).
doi: 10.1016/0024-3205(81)90589-0
Schaeffer, P. et al. Human umbilical vein endothelial cells express high affinity neurotensin receptors coupled to intracellular calcium release. J. Biol. Chem. 270(7), 3409–3413 (1995).
pubmed: 7852427
doi: 10.1074/jbc.270.7.3409
Rioux, F., Kérouac, R. & St-Pierre, S. Analysis of the biphasic depressor–pressor effect and tachycardia caused by neurotensin in ganglion- blocked rats. Neuropeptides 3, 113127 (1982).
doi: 10.1016/0143-4179(82)90007-5
Donelan, J. et al. Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proc. Natl. Acad. Sci. U S A 103, 7759–7764 (2006).
pubmed: 16682628
pmcid: 1472518
doi: 10.1073/pnas.0602210103
Vincent, J. P., Mazella, J. & Kitabgi, P. Neurotensin and neurotensin receptors. Trends Pharmacol. Sci. 20, 302309 (1999).
doi: 10.1016/S0165-6147(99)01357-7
Goettsch, C., Kjolby, M. & Aikawa, E. Sortilin and its multiple roles in cardiovascular and metabolic diseases. Arterioscler. Thromb. Vasc. Biol. 38(1), 19–25 (2018).
pubmed: 29191923
doi: 10.1161/ATVBAHA.117.310292
Liu, C., Xiong, X. & Li, J. Regulation of atherosclerosis development by neurotensin derived from lymphatic endothelial cells in mice. Arterioscler. Thromb. Vasc. Biol. 43(9), 1743–1745 (2023).
pubmed: 37534467
pmcid: 10443625
doi: 10.1161/ATVBAHA.123.319527
Ernst, A., Hellmich, S. & Bergmann, A. Proneurotensin 1–117, a stable neurotensin precursor fragment identified in human circulation. Peptides 27, 17871793 (2006).
Barchetta, I. et al. Circulating pro-neurotensin levels predict bodyweight gain and metabolic alterations in children. Nutr. Metab. Cardiovasc. Dis. 31, 902910 (2021).
doi: 10.1016/j.numecd.2020.11.025
Nicoli, C. D. et al. Pro-neurotensin/neuromedin n and risk of incident metabolic syndrome and diabetes mellitus in the REGARDS cohort. J. Clin. Endocrinol. Metab. 106(9), e3483–e3494 (2021).
pubmed: 34013344
pmcid: 8372646
doi: 10.1210/clinem/dgab355
Melander, O. et al. Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. JAMA 308, 14691475 (2012).
doi: 10.1001/jama.2012.12998
Barchetta, I. et al. Increased plasma proneurotensin levels identify NAFLD in adults with and without Type 2 diabetes. J. Clin. Endocrinol. Metab. 103, 2253–2260 (2018).
pubmed: 29590379
doi: 10.1210/jc.2017-02751
De Vito, F. et al. Higher circulating levels of proneurotensin are associated with increased risk of incident NAFLD. J. Intern. Med. 294(3), 336–346 (2023).
pubmed: 37157165
doi: 10.1111/joim.13651
Januzzi, J. L. Jr. et al. Circulating proneurotensin concentrations and cardiovascular disease events in the community: The Framingham Heart Study. Arterioscler. Thromb. Vasc. Biol. 36, 16921697 (2016).
doi: 10.1161/ATVBAHA.116.307847
Nicoli, C. D. et al. Pro-neurotensin/neuromedin N and risk of ischemic stroke: The REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Vasc. Med. 25, 534540 (2020).
doi: 10.1177/1358863X20957406
Fawad, A. et al. Proneurotensin predicts cardiovascular disease in an elderly population. J. Clin. Endocrinol. Metab. 103(5), 1940–1947 (2018).
pubmed: 29546332
doi: 10.1210/jc.2017-02424
Musunuru, K. et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 466(7307), 714–719 (2010).
pubmed: 20686566
pmcid: 3062476
doi: 10.1038/nature09266
Wang, L. J. et al. Identification of U-shaped curve relation between proneurotensin and risk of coronary artery disease (CAD) in patients with premature CAD. Nutr. Metab. Cardiovasc. Dis. 30, 483491 (2020).
doi: 10.1016/j.numecd.2019.10.009
Lorenz, M. W., Markus, H. S., Bots, M. L., Rosvall, M. & Sitzer, M. Prediction of clinical cardiovascular events with carotid intima-media thickness: A systematic review and meta-analysis. Circulation 115(4), 459–467 (2007).
pubmed: 17242284
doi: 10.1161/CIRCULATIONAHA.106.628875
Fernández-Alvarez, V. et al. Evaluation of intima- media thickness and arterial stiffness as early ultrasound biomarkers of carotid artery atherosclerosis. Cardiol. Ther. 11(2), 231–247 (2022).
pubmed: 35362868
pmcid: 9135926
doi: 10.1007/s40119-022-00261-x
Agarwal, N., St John, J., Van Iterson, E. H. & Laffin, L. J. Association of pulse pressure with death, myocardial infarction, and stroke among cardiovascular outcome trial participants. Am. J. Prev. Cardiol. 17, 100623 (2023).
pubmed: 38144432
pmcid: 10746405
doi: 10.1016/j.ajpc.2023.100623
Said, M. A., Eppinga, R. N., Lipsic, E., Verweij, N. & van der Harst, P. Relationship of arterial stiffness index and pulse pressure with cardiovascular disease and mortality. J. Am. Heart Assoc. 7(2), e007621 (2018).
pubmed: 29358193
pmcid: 5850166
doi: 10.1161/JAHA.117.007621
Wong, Y. K. & Tse, H. F. Circulating biomarkers for cardiovascular disease risk prediction in patients with cardiovascular disease. Front. Cardiovasc. Med. 8, 713191 (2021).
pubmed: 34660715
pmcid: 8517145
doi: 10.3389/fcvm.2021.713191
Mortensen, M. B. et al. Targeting sortilin in immune cells reduces proinflammatory cytokines and atherosclerosis. J. Clin. Invest. 124(12), 5317–5322 (2014).
pubmed: 25401472
pmcid: 4348947
doi: 10.1172/JCI76002
Goettsch, C. et al. Sortilin mediates vascular calcification via its recruitment into extracellular vesicles. J. Clin. Invest. 126(4), 1323–1336 (2016).
pubmed: 26950419
pmcid: 4811143
doi: 10.1172/JCI80851
Polak, J. F. et al. Carotid-wall intima-media thickness and cardiovascular events. N. Engl. J. Med. 365(3), 213–221 (2011).
pubmed: 21774709
pmcid: 3153949
doi: 10.1056/NEJMoa1012592
Kokubo, Y. et al. Impact of intima-media thickness progression in the common carotid arteries on the risk of incident cardiovascular disease in the Suita study. J. Am. Heart Assoc. 7(11), e007720 (2018).
pubmed: 29858361
pmcid: 6015343
doi: 10.1161/JAHA.117.007720
Kosmas, C. E. et al. Insulin resistance and cardiovascular disease. J. Int. Med. Res. 51(3), 3000605231164548 (2023).
pubmed: 36994866
doi: 10.1177/03000605231164548
Lee, H. S. & Lee, J. H. Early elevation of high-sensitivity C-reactive protein as a predictor for cardiovascular disease incidence and all-cause mortality: A landmark analysis. Sci. Rep. 13(1), 14118 (2023).
pubmed: 37644061
pmcid: 10465521
doi: 10.1038/s41598-023-41081-w
Alfaddagh, A. et al. Inflammation and cardiovascular disease: From mechanisms to therapeutics. Am. J. Prev. Cardiol. 4, 100130 (2020).
pubmed: 34327481
pmcid: 8315628
doi: 10.1016/j.ajpc.2020.100130
Jubaidi, F. F. et al. The role of PKC-MAPK signalling pathways in the development of hyperglycemia-induced cardiovascular complications. Int. J. Mol. Sci. 23(15), 8582 (2022).
pubmed: 35955714
pmcid: 9369123
doi: 10.3390/ijms23158582
Osadchii, O., Norton, G., Deftereos, D., Muller, D. & Woodiwiss, A. Impact of chronic beta-adrenoceptor activation on neurotensin-induced myocardial effects in rats. Eur. J. Pharmacol. 553(1–3), 246–253 (2006).
pubmed: 17056037
doi: 10.1016/j.ejphar.2006.09.037
Ciriello, J. & Zhang, T. X. Cardiovascular effects of neurotensin microinjections into the nucleus of the solitary tract. Brain Res. 749(1), 35–43 (1997).
pubmed: 9070625
doi: 10.1016/S0006-8993(96)01176-6
Kaczyńska, K. & Szereda-Przestaszewska, M. Cardio-respiratory effects of systemic neurotensin injection are mediated through activation of neurotensin NTS1 receptors. Eur. J. Pharmacol. 691(1–3), 245–250 (2012).
pubmed: 22819705
doi: 10.1016/j.ejphar.2012.07.020
Varzideh, F. et al. Sortilin drives hypertension by modulating sphingolipid/ceramide homeostasis and by triggering oxidative stress. J. Clin. Invest. 132(3), e156624 (2022).
pubmed: 35104807
pmcid: 8803317
doi: 10.1172/JCI156624
Fiorentino, T. V. et al. One-hour post-load hyperglycemia combined with HbA1c identifies pre-diabetic individuals with a higher cardio-metabolic risk burden. Atherosclerosis 253, 61–69 (2016).
pubmed: 27588935
doi: 10.1016/j.atherosclerosis.2016.08.020
American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2020. Diabetes Care 43, S14–S31 (2020).
doi: 10.2337/dc20-S002
Mancia, G. et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 34, 2159–2219 (2013).
pubmed: 23771844
doi: 10.1093/eurheartj/eht151
Matsuda, M. & De Fronzo, R. A. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. Diabetes Care 22, 1462–1470 (1999).
pubmed: 10480510
doi: 10.2337/diacare.22.9.1462